- Home
- NGEN vs NGNE Comparison
NGEN vs NGNE Comparison
Compare NGEN & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NGEN | NGNE |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.6M | 327.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NGEN | NGNE |
|---|---|---|
| Price | $4.21 | $21.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $60.13 |
| AVG Volume (30 Days) | 114.9K | ★ 128.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $925,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.73 | $6.88 |
| 52 Week High | $5.93 | $37.27 |
Technical Indicators
Market Signals| Indicator | NGEN | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 39.96 | 57.57 |
| Support Level | $3.73 | $19.44 |
| Resistance Level | $4.50 | $20.87 |
| Average True Range (ATR) | 0.25 | 1.67 |
| MACD | 0.05 | 0.56 |
| Stochastic Oscillator | 50.00 | 45.10 |
Price Performance
Historical ComparisonAbout NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.